Ocular comorbidities are common in multiple myeloma: results of a large cross-sectional survey
Abstract Both advancing age and multiple myeloma (MM) therapies such as belantamab mafodotin or dexamethasone can be risk factors for ocular complications. We conducted an international online survey of 508 patients with MM; 3% and 2% reported previous craniofacial radiation therapy or belantamab mafodotin, respectively. Common ocular comorbidities included cataracts (59%), dry eyes requiring eyedrops (37%), and blepharitis or styes (24%). Higher typical dexamethasone doses (≥20 milligrams weekly) were associated with cataracts after adjusting for advancing age and time since diagnosis. Compared to lower-dose dexamethasone (0-19 milligrams weekly), high-dose dexamethasone shifted the incidence curve of predicted cataracts approximately 5.4 years earlier. Although 82% of patients reported periodic eye exams (in line with ophthalmologic recommendations for older adults), only 31% had ever received such guidance from their MM teams. In conclusion, ocular issues are common in MM. Corticosteroid-sparing regimens may warrant attention across the age spectrum to reduce the risk of cataracts.
Authors
- Jennifer M. Ahlstrom
- Rahul Kumar Banerjee (ORCID: https://orcid.org/0000-0003-3781-5441)
- Andrew J. Cowan (ORCID: https://orcid.org/0000-0002-1880-7094)
- Parisa Taravati (ORCID: https://orcid.org/0000-0002-0263-4344)
- Kara I. Cicero (ORCID: https://orcid.org/0000-0003-3030-3005)
- Mason Barnes
- Jorge Arturo Hurtado Martínez
- Gurbakhash Kaur
- Patricia Alejandra Flores Pérez
- Jay Hydren
Institutions
- BC Cancer Agency (CA)
- University of Washington (US)
- Fred Hutch Cancer Center (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- The Oncologist
- Published
- 2026-11-13
- DOI
- https://doi.org/10.1093/oncolo/oyag458
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00